Certara, Inc. $CERT Shares Bought by Pier Capital LLC

Pier Capital LLC grew its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 13.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 754,600 shares of the company’s stock after buying an additional 87,178 shares during the period. Certara accounts for about 1.4% of Pier Capital LLC’s holdings, making the stock its 17th largest holding. Pier Capital LLC owned about 0.47% of Certara worth $9,221,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. AQR Capital Management LLC acquired a new stake in shares of Certara during the 1st quarter worth about $259,000. Goldman Sachs Group Inc. increased its stake in Certara by 65.6% in the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after purchasing an additional 90,724 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Certara by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock valued at $2,965,000 after purchasing an additional 35,954 shares during the last quarter. Jane Street Group LLC raised its holdings in Certara by 17.1% during the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after purchasing an additional 40,463 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Certara by 25.3% during the second quarter. PNC Financial Services Group Inc. now owns 25,783 shares of the company’s stock worth $302,000 after purchasing an additional 5,201 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Stock Down 1.5%

CERT opened at $6.56 on Friday. Certara, Inc. has a 52 week low of $6.04 and a 52 week high of $15.38. The business has a 50 day moving average price of $8.02 and a two-hundred day moving average price of $9.64. The company has a quick ratio of 2.05, a current ratio of 2.05 and a debt-to-equity ratio of 0.27. The company has a market cap of $1.04 billion, a PE ratio of -656.00 and a beta of 1.50.

Certara (NASDAQ:CERT) last announced its earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). The company had revenue of $103.65 million during the quarter, compared to analysts’ expectations of $103.23 million. Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.15 earnings per share. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Craig Hallum cut shares of Certara from a “buy” rating to a “hold” rating and set a $10.00 target price for the company. in a report on Friday, February 27th. Leerink Partners reiterated an “outperform” rating and set a $10.00 price target on shares of Certara in a research note on Thursday, February 26th. Barclays reissued an “equal weight” rating and issued a $8.00 price target on shares of Certara in a research report on Friday, March 6th. Stephens decreased their price objective on shares of Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, December 12th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Certara presently has an average rating of “Hold” and an average price target of $11.10.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.